Neoplasia-Associated Pericarditis—Predictor of Cancer Progression?

Diagnostics

ConstantinTudor Luca¹  AlinaGabriela Negru¹  Laura Mazilu²  ȘerbanMircea Negru³  Dorel Popovici³  Sorin Săftescu³  Anca Tudor⁴  Anca Boldan⁵  Maria Boldan⁶ 

[1] Department of Cardiology, University of Medicine and Pharmacy, 300041 Timișoara, Romania;Department of Oncology, Faculty of Medicine, Ovidius University of Constanta, 900470 Constanța, Romania;Department of Oncology, University of Medicine and Pharmacy “Victor Babeș”, 300041 Timișoara, Romania;Discipline of Computer Science and Medical Biostatistics, University of Medicine and Pharmacy, 300041 Timișoara, Romania;Oncomed Oncology Outpatient Clinic, 300239 Timișoara, Romania;University of Medicine and Pharmacy Timișoara Student, 300041 Timișoara, Romania;

关键词: pericarditis;    cancer;    cancer progression;    neoplasia;    cardio-oncology;    pericarditis marker of cancer progression/recidive;   

DOI  :  10.3390/diagnostics11010058

来源: DOAJ

【 摘 要 】

Pericarditis may signal the presence of cancer, even in the absence of other clinical or paraclinical signs. Corollary, the following question arises: Could the discovery of a newly developed pericarditis be used in patients with known neoplasia as a marker of cancer progression? In an attempt to find an answer to this question, this two-centre study included 341 consecutive patients with a confirmed diagnosis of cancer and evidence of pericardial effusion at echocardiography and/or CT/MRI scan. The patients’ data were collected retrospectively if they further fulfilled the following inclusion criteria: available medical data from confirmation of pericarditis until evidence of cancer progression or until at least 12 months without progression. The average age of the patients was 62.16 years (22–86 years), and the study comprised 44.28% males and 55.71% females. All types of the most common neoplasms were represented. The results showed that 85.33% of patients had cancer progression temporally linked to pericarditis. Of these, 41.64% had cancer progression within 18 months after the diagnosis of pericarditis with a median time to progression of 5.03 months, ranging from 0 to 17 months; 43.69% had progression within a maximum of 2 months before the diagnosis of pericarditis. Only 14.66% had no cancer progression during the observation period. We concluded that pericarditis could be a sensitive marker of cancer evolution that could be widely used as a follow-up investigation for cancer patients as a marker of progression or recidive.

【 授权许可】

Unknown